About
Histosonics

Origin of histotripsy

A walking path on The University of Michigan
The science of histotripsy was developed by leading ultrasound scientists from the University of Michigan as a non-invasive potential alternative to certain surgical procedures.

Translating science to clinical practice

Leading multi-disciplinary clinicians from the University of Wisconsin and the University of Michigan collaborate through ongoing partnerships with HistoSonics to bring histotripsy into everyday clinical practice.
Medical screen

Executive Team

Male professional headshot

Mike Blue

President, CEO Board Member
Male professional headshot

Josh Stopek, PhD

VP of Research and Development
Male professional headshot

Josh King

VP of Global Market Access
Male professional headshot

Michele Bossert

VP of Education
Male professional headshot

Dan Bulver

VP of Operations
Male professional headshot

Dan Kosednar

VP of Regulatory Affairs
Male professional headshot

Donald Hayden

VP of Sales
Male professional headshot

Joe Herman MD

VP of Medical Affairs
Male professional headshot

David Krenn

Chief Financial Officer
Male professional headshot

Barbara Peterson

VP of Reimbursement
Male professional headshot

Amanda Cafaro

VP of Clinical Affairs

BOARD OF DIRECTORS

Male professional headshot

Jim Adox

Chairman of the Board (HistoSonics) Managing Director - Venture Investors, LLC
Male professional headshot

Mike Blue

President, CEO HistoSonics
Male professional headshot

Kadir Kadhiresan, PhD

Vice President Johnson & Johnson Innovation – JJDC, Inc.
Male professional headshot

Tom Tefft

Former President Medtronic Neuromodulation
Male professional headshot

Gerry Brunk

Managing Director Lumira Ventures
Male professional headshot

Erica Rogers

President and CEO Silk Road Medical
Male professional headshot

David Hahn, MD

Chief Medical Officer Varian Interventional Solutions - Varian Medical Systems
Male professional headshot

Fred Lee Jr., MD

Senior Medical Advisor HistoSonics
Male professional headshot

Wen Chen

Partner Yonjin Venture

INVESTORS

Venture Investors Healthfund
Venture Investors Healthfund

Premier provider of seed and early stage venture capital to healthcare companies.

Lumira Ventures
Lumira Ventures

Partners & invests in best-in-class innovative biotherapeutic & medtech entrepreneurs building transformative companies.

Varian Medical Systems
Varian Medical Systems

Applying human ingenuity to help you elevate cancer care.

Johnson & Johnson Innovation, JJDC
Johnson & Johnson Innovation, JJDC

Investing in and supporting the global entrepreneurial community to solve critical healthcare needs.

Yonjin Venture
Yonjin Venture

Specializes in early and mid-stage life science companies. We are interested in innovative technologies in therapeutics, diagnostics and medical devices.

TGap Ventures
TGap Ventures

Helps entrepreneurs define, develop, grow, and build value in their businesses, principally in medicine healthcare technology.

Fletcher Spaght Ventures
Fletcher Spaght Ventures

Investing in promising new ventures in emerging technologies with high growth potential.

Early Stage Partners
Early Stage Partners

Provides early stage venture capital to promising entrepreneurial companies in healthcare technology and other fields.

Hatteras Venture Partners
Hatteras Venture Partners

Building transformational human medicine companies that benefit patients and the professionals who serve them.

Ready to learn more about us?
Connect with the HistoSonics team.

Contact Us

Last updated on January 2, 2024

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

Footer last updated on November 8, 2023
X New Twitter Logo
© 2019-2023 HistoSonics®. All rights reserved.